Sanofi: Test Shows Efficiency Of Diabetes Drug

French drug company Sanofi SA Friday said new data show its diabetes drug Lantus was more efficient than other forms of care for reaching certain glycemic levels in patients.

Results from the company’s ORIGIN trial, which focused on care of patients with pre-diabetes or early type 2 diabetes and were presented at the annual meeting of the European Association for the Study of Diabetes, showed that the drug was three times more likely to reach and maintain glycemic targets than standard care, the company said in a statement.

Facing the loss of patent expiries of some of its top-selling drugs, including Lantus in 2014, Sanofi has sought to shore up business in areas such as animal health, over-the-counter treatments and vaccines. The company also considers diabetes treatment as one of its main sources of future growth.

Market Watch